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http://www.biomedcentral.com/1755-8794/6/25RESEARCH ARTICLE Open AccessGenetic lineages of undifferentiated-type gastric
carcinomas analysed by unsupervised clustering
of genomic DNA microarray data
Ayano Sonoda1,2, Ken-ichi Mukaisho1, Takahisa Nakayama1, Vo Thi Ngoc Diem1, Takanori Hattori1, Akira Andoh2,
Yoshihide Fujiyama2 and Hiroyuki Sugihara1*Abstract
Background: It is suspected that early gastric carcinoma (GC) is a dormant variant that rarely progresses to
advanced GC. We demonstrated that the dormant and aggressive variants of tubular adenocarcinomas (TUBs) of
the stomach are characterized by loss of MYC and gain of TP53 and gain of MYC and/or loss of TP53, respectively.
The aim of this study is to determine whether this is also the case in undifferentiated-type GCs (UGCs) of different
genetic lineages: one with a layered structure (LS+), derived from early signet ring cell carcinomas (SIGs), and the
other, mostly poorly differentiated adenocarcinomas, without LS but with a minor tubular component (TC),
dedifferentiated from TUBs (LS−/TC+).
Methods: Using 29 surgically resected stomachs with 9 intramucosal and 20 invasive UGCs (11 LS+ and 9 LS−/TC+),
63 genomic DNA samples of mucosal and invasive parts and corresponding reference DNAs were prepared from
formalin-fixed, paraffin-embedded tissues with laser microdissection, and were subjected to array-based
comparative genomic hybridization (aCGH), using 60K microarrays, and subsequent unsupervised, hierarchical
clustering. Of 979 cancer-related genes assessed, we selected genes with mean copy numbers significantly different
between the two major clusters.
Results: Based on similarity in genomic copy-number profile, the 63 samples were classified into two major
clusters. Clusters A and B, which were rich in LS+ UGC and LS−/TC+ UGC, respectively, were discriminated on the
basis of 40 genes. The aggressive pattern was more frequently detected in LS−/TC+ UGCs, (20/26; 77%), than in LS+
UGCs (17/37; 46%; P = 0.0195), whereas no dormant pattern was detected in any of the UGC samples.
Conclusions: In contrast to TUBs, copy number alterations of MYC and TP53 exhibited an aggressive pattern in LS+
SIG at early and advanced stages, indicating that early LS+ UGCs inevitably progress to an advanced GC. Cluster B
(enriched in LS−/TC+) exhibited more frequent gain of driver genes and a more frequent aggressive pattern than
cluster A, suggesting potentially worse prognosis in UGCs of cluster B.Background
Gastric carcinoma (GC) have been classified histologi-
cally into intestinal, diffuse and unclassified types by
Lauren [1] and the unclassified type was further divided
into solid and mixed types by Carneiro [2]. The
undifferentiated-type gastric carcinoma (UGC) accor-
ding to the Japanese classification [3] mostly overlaps
poorly differentiated GC, which comprises not only the* Correspondence: sugihara@belle.shiga-med.ac.jp
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reproduction in any medium, provided the ordiffuse type including signet ring cell carcinoma (SIG)
but also the solid type and the mixed type with minor
tubular component (TC).
Recently it has been proposed that advanced diffuse-
type GC may derive from either early diffuse-type or
intestinal-type GC. Well differentiated tubular adeno-
carcinoma (TUB) can transform into poorly differenti-
ated adenocarcinoma (POR) after the silencing of cell
adhesion-related genes including CDH1 [4,5]. Carneiro’s
mixed type carcinomas may thus overlap dedifferentiated
TUBs. It has been reported that the survival rate of the pa-
tients with mixed-type GCs was significantly lower thanl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the survival rate of early GC patients with SIG was
higher than that of GC patients without SIG [6]. Thus
UGCs may be divided into subgroups with different
prognosis. Recently, a mass-screening program for
neuroblastomas [7-9] was suspended in Japan because
a discontinuous genetic lineage was observed between
the early- and the late-presenting neuroblastomas. Ne-
gative and late-presenting (≥1 year) neuroblastomas
exhibited near-diploidy with terminal 1p deletion,
whereas positive neuroblastomas in infants exhibited
near-triploidy without 1p deletion [10,11]. To perform
such subgrouping, we have classified UGCs based on
the continuity of genetic lineages as well as the expres-
sion of morphological lineage markers.
Our lineage analysis using chromosomal comparative
genomic hybridization (CGH) was based on distinctive
morphological lineage markers. A layered structure
(LS) represents an incipient phase of SIG development
[12] and is commonly retained even at an advanced
stage in the human stomach. In tumour regions with
LS, the mode of cell proliferation resembles that in the
normal gastric mucosa. And it is believed that tumour
cells remain confined to the mucosa as far as they grow
to form the LS [13]. Our lineage analyses confirmed
that POR with LS was derived from intramucosal SIG,
whereas POR without LS and with a minor TC (< 30%),
was derived from TC [14,15]. However, the TC was not
always derived from early TUB but could also be
derived from SIG, whereas LS was scarcely derived
from TUB [15]. Therefore, as a morphological lineage
marker, LS may take priority over TC. In addition,
UGCs without LS or TC due to secondary loss of these
markers are observed, which prompted us to adopt
array CGH (aCGH) and unsupervised cluster analyses
of the aCGH data to classify UGCs solely on the basis
of similarity in the genomic copy number profile.
In differentiated-type gastric carcinomas (DGCs), our
recent aCGH-based lineage analyses revealed two genetic
lineages: one with copy-number loss of MYC and copy-
number gain of TP53 (MYC− and TP53+), a dormant
pattern, and the other with the copy-number gain of MYC
and/or copy-number loss of TP53 (MYC+ and/or TP53−),
an aggressive pattern. The dormant pattern accounted
for 70% of intramucosal carcinoma samples and a half
of the intramucosal part samples of invasive carcin-
omas. The invasive parts of invasive carcinomas mostly
exhibited the aggressive copy number alteration (CNA)
pattern. When the intramucosal part of an advanced
cancer was dormant, the lineage was discontinuous be-
tween the mucosal and invasive parts. Therefore, the
MYC−/TP53+ and MYC+ and/or TP53− CNA patterns
may be signatures of dormant and aggressive TUBs,
respectively [16].In the present study, genomic DNA samples from the
mucosal and invasive parts of early and advanced UGCs
were prepared and subjected to gene copy-number ana-
lyses using aCGH, followed by unsupervised cluster ana-
lysis of the aCGH data. Based on these results, we
examined relationship between morphological and gen-
etic lineage markers and identified several useful lineage
marker genes for UGC.
Methods
The Institutional Review Board on Medical Ethics at
Shiga University of Medical Science approved this study
on the condition that the UGC samples used were an-
onymous. Written informed consent was not required
because this retrospective study used archival samples.
Tissue samples
This study included 29 surgically resected, buffered
formalin-fixed, paraffin embedded UGCs: 20 with LS in
at least part of the tumour (LS+, 9 intramucosaltumours
and 11 invasive tumours) and 9 without LS but con-
taining a small TC (LS−/TC+, all invasive tumours)
(Table 1). TC was defined as a well or moderately differ-
entiated adenocarcinoma component comprising ≤ 30% of
the entire tumour [15]. All samples were selected from
GC cases diagnosed in our department from 1997 to
2011. Intramucosal LS+UGC patients averaged 57.6 years
of age (range, 48–79) and patients with invasive LS+
UGCs 60.2 years (range, 48–79) and patients with inva-
sive LS−/TC+ UGCs 62.2 years (range; 50–75). The
macroscopic classification was determined according
to the Japanese Classification of Gastric Cancer with
TNM staging [3].
LS evaluation
LS was defined as in a previous study [17]. In brief,
LS+ regions had small carcinoma cells confined to the
stroma at the gland-neck level that gradually differenti-
ated to signet ring cells in the superficial (and deep)
lamina propria (Figure 1a). The absence of LS in
intramucosal regions of the tumour was defined by
four patterns: 1) contact of small carcinoma cells to
the muscularis mucosae in SIG, 2) mucinous adeno-
carcinoma, 3) POR and 4) the presence of a TC
(Figure 1b-f ).
Laser microdissection and DNA preparation
Tumour tissue samples were obtained from 5-μm-thick
tissue sections using a LMD6000 laser microdissection
system (Leica Microsystems, Wetzlar, Germany). For in-
vasive cancers, DNA samples were obtained from both
the intramucosal and invasive parts. For each sample,
cancer tissues were obtained from an area >6 mm2, in
which cancer cells accounted for ≥70% of the total cell
Table 1 Summary of clinicopathological characteristics of 29 UGCs
Case
no
Age/
sex
Size of
mucosal
lesion
(cm)
Macroscopic
type*
Histological type* Sampling region for aCGH Depth of
invasion†
LN
meta†
Stage†
Intramucosal part Invasive
partLS not LS TC
M101 79/F 8.5 × 4.0 0(IIc) SIG > TC + NT NT T1 (m) N0 IA
M102 48/F 9.5 × 5.0 0(IIc) SIG > POR1 + NT - T1 (m) N0 IA
M103 57/M 1.4 × 0.8 0(IIc) SIG + NT - T1 (m) N0 IA
M104 76/F 6.0 × 5.0 0(IIc) SIG + NT - T1 (m) N0 IA
M105 50/M 1.5 × 1.2 0(IIc) SIG + NT - T1 (m) N0 IA
M106 60/F 1.2 × 1.0 0(IIc) SIG + - - T1 (m) N0 IA
M107 49/F 4.0 × 2.5 0(IIc + III) SIG > POR1 + NT - T1 (m) N0 IA
M108 48/F 6.0 × 2.8 0(IIc) SIG > POR1 > TC + POR NT T1 (m) N0 IA
M109 51/M 5.3 × 3.3 0(IIc + III) SIG + SIG - T1 (m) N0 IA
SM101 71/F 0.9 × 0.8 0(IIc) SIG > POR2 + NT - NT T1 (sm2) N2 II
A102 72/F 5.0 × 3.0 0(IIc + IIb) POR2 > POR1 > SIG + SIG - POR2 T2 (mp) N1 II
A103 79/F 12.0 × 8.5 0(IIa + IIb) POR1 > TC > SIG > POR2 + POR NI NT T2 (mp) N1 II
A104 49/M 2.8 × 2.5 0(IIc + III) SIG > POR2 > TC + NT NT POR2 T2 (ss) N1 II
SM105 59/F 11.5 × 7.0 0(IIa + IIc) SIG > TC > POR2 + TUB2 NT POR2 T1 (sm) N1 IB
SM106 72/M 3.7 × 2.3 0(IIc) SIG > POR1 + POR - NT T1 (sm2) N0 IA
A107 48/F 12.0 × 6.5 0(IIc + III) SIG > POR2 > POR1 > MUC + POR - POR2 T3 (se) N2 IIIB
A108 46/M 4.0 × 2.8 0(IIc + III) POR2 > POR1 > SIG NI NI - POR2 T2 (mp) N2 IIIA
A109 55/M 3.8 × 3.3 0(IIc + III) SIG > POR1 + POR - SIG T1 (sm2) N0 IA
A110 57/M 5.5 × 2.2 0(IIc) POR2 > SIG > TC + POR - POR2 T2 (mp) N1 II
A111 54/F 8.0 × 7.0 3 POR2 > SIG + POR - POR2 T3 (se) N2 IIIB
SM201 75/F 3.7 × 3.0 2 POR1 > TC - POR/TUB2 + POR T1 (sm2) N0 IA
A202 60/M 4.0 × 3.8 0(IIc) POR2 > POR1 > TC > SIG - POR/TUB2 + POR T2 (mp) N0 IB
SM203 71/M 4.5 × 2.0 0(IIa + IIc) POR1 > TC > SIG - POR/TUB2 + POR T1 (sm2) N0 IA
A204 65/F 5.5 × 3.0 3 POR2 > TC > POR1 - POR/TUB2 + POR T3 (se) N3 IV
A205 54/M 7.4 × 5.8 5 POR2 > TC > POR1 - POR/TUB2 + POR T3 (se) N0 II
A206 67/F 5.5 × 4.0 4 POR2 > TC > POR1 - POR/TUB2 + NT T4 (si) N2 IV
A207 52/M 6.0 × 4.0 4 POR1 > POR2 > SIG > TC - POR/TUB2 + POR T3 (se) N3 IV
A208 75/M 9.0 × 7.0 2 POR1 > TC - POR/TUB2 + POR T2 (mp) N1 II
A209 50/F 2.3 × 0.8 3 POR2 > SIG > POR1 > TC - POR/TUB2 + POR T2 (mp) N2 IIIA
*Japanese classification of gastric carcinoma, modified.
†TNM classification.
UGCs, Undifferentiated gastric carcinomas; aCGH, Array CGH; LN, Lymph node, LS, Layered structure; TC, Tubular component; SIG, Signet ring cell carcinoma; POR,
Poorly differentiated adenocarcinoma; POR1, Solid POR; POR2, Non-solid POR; TUB2, Moderately differentiated adenocarcinoma; MUC, Mucinous adenocarcinoma;
m, mucosa; sm, submucosa; mp, muscular propria; ss, subserora; se, serosal exposure; si, invasion to adjacent structures; M, Male; F, Female; NT, Not tested; NI,
Not informative.
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teinase K solution for approximately 72 hours at 37.0°C
and genomic DNA extracted with phenol/chloroform.
Whole genome amplification
Sample DNA was amplified using the GenomePlex
Whole Genome Amplification Kit (WGA2 Kit; Sigma,
St. Louis, USA) [18]. For some DNA samples that could
not be sufficiently amplified, the WGA5 Kit (Sigma)
was employed.Array CGH
An oligo CGH microarray (60K, 60-mer) (Agilent,
Santa Clara, USA) was used in this study, according
to the manufacturer's instructions. In brief, the amp-
lified tumour and control DNA samples were non-
enzymatically labelled with Cy5 and Cy3, respectively,
using the Genome DNA ULS Labelling Kit (Agilent)
and competitively hybridized to the microarray. The
hybridized array images were captured using a DNA
microarray scanner (Agilent) and then the fluorescence
Figure 1 Histological appearances of intramucosal parts of undifferentiated-type gastric carcinomas (UGCs). A signet ring cell carcinoma
(SIG) component with a layered structure in case A107 (a). Small carcinoma cells are distributed in the deeper part just above or in the muscularis
mucosae in a SIG component in case M109 (b). A mucinous adenocarcinoma component in case A107 (c). A poorly differentiated
adenocarcinoma component in case SM106 (d). Minor tubular components in cases SM105 and SM201, respectively (e, f).
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was calculated by Feature Extraction Ver.9.5.3 (Agilent).
The array data were normalized using Genomic Work-
bench software Ver.5.0 (Agilent). The positions of olig-
omers are based on the Human Genome February
2009 assembly (hg19). Copy-number gains and losses
were defined as changes in the logarithm to the base 2
of the tumour to reference signal intensity ratio (T/R)
greater than 0.3219 and less than −0.3219, respectively. LS+ UGCs
50
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Figure 2 Frequency of copy-number alterations at the chromosome l
chromosome in the LS+ UGCs (a) and LS−/TC+ UGCs (b). Gains and lossesCluster analysis
To perform novel subtyping of UGC samples based on
genomic profile similarity in this study, an unsuper-
vised hierarchical cluster analysis was applied across 63
samples from 29 UGC cases by using the Cluster 3.0
and TreeView software programs. The clustering algo-
rithm was set to complete linkage clustering using an
uncentered correlation. To enable unsupervised cluster
analysis, we performed unbiased reduction in probe24
24
12p12
evel. The percentage of the samples that have CNAs for each
are indicated with red and green, respectively.
Intramucosal LS+ UGCs
Invasive LS+ UGCs
Invasive LS-/TC+ UGCs
Cluster A Cluster B
Figure 3 Unsupervised hierarchical cluster analysis of array-based comparative genomic hybridization (aCGH) data. Gene copy-number
gains and losses are indicated by red and green, respectively. A total of 63 samples from 29 UGCs were classified into two major clusters: A and
B. Most samples of LS+ UGCs were included in cluster A and most LS−/TC+ UGCs samples were in cluster B. All the Intramucosal LS+ UGCs were
included in cluster A.
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probes. For this purpose, we selected large genes be-
cause the greater number of corresponding probes
resulted in improved signal-to-noise ratio of the repre-
sentative gene copy numbers. The unsupervised strat-
egy enabled us to set an internal standard to validate
clustering results; the copy number profiles in samples
of the same tumour should be more similar than any
copy number profiles from another tumour because
the gene alterations in the process of carcinogenesis
are largely common among the samples from the same
tumour.
Statistical analyses
Differences in contingency tables were assessed for statis-
tical significance using Fisher's exact test. A P < 0.05 (2-
sided) was considered statistically significant. The Welch’s
t test was used to evaluate the difference in mean DNA
copy number for each probe between two clusters of sam-
ples. The Bonferroni correction was used to correct for
multiple comparisons.Results
Samples analysed with array CGH
Tissue samples were excised from 29 archived GC speci-
mens by laser microdissection. The tissue sample popu-
lation included 11 regions (from 9 intramucosal SIGs),
of which 9 regions were LS+ and the other two LS−, 26
regions (from 11 LS+ invasive UGC), of which 10 were
LS+mucosal regions, 8 were LS−mucosal regions and 8
were invasive regions, and 26 regions (from 9 LS−/TC+
invasive UGCs): 9 intramucosal POR, 9 intramucosal TC
and 8 invasive regions.
Genome wide copy number alterations
A plot of the genetic aberration penetrance for all chromo-
somes is shown for LS+UGCs and LS−/TC+UGCs in
Figure 2a and Figure 2b, respectively. Copy-number gains
and losses were more common in LS−/TC+UGCs than in
LS+UGCs. The most frequent copy-number gains were
detected at 3q26 (7/63 samples), 5p15 (8/63), 8p23 (9/63),
8q24 (7/63) and 12p12 (6/63), while the most frequent copy-
number losses were found at 7q36 (5/63) and 12p12 (5/63).
M101 M102 M103 M104 M105 M106 M107 M108 M109
TP53 -0.34555 0.08225 -0.07102 -0.42086 -0.31831 -0.15595 -0.25034 -0.05623 -0.08278
MYC 0.28869 0.60689 -0.12499 0.26935 0.34773 -0.01566 0.03396 0.28600 -0.01045
M108 M109
TP53 -0.61834 -0.89144
MYC 0.09889 0.21814
SM101 SM105 SM106 SM109 A102 A103 A104 A107 A110 A111
TP53 -0.04180 0.59827 -0.50626 -0.84266 -0.02558 0.29978 0.24469 -0.07716 -0.08916 0.02225
MYC -0.25511 0.01471 0.08768 0.33573 0.00061 -0.31085 -0.04286 0.33741 -0.08619 -0.19611
SM105TC SM106POR SM109POR A102MMC A103POR A107MMC A110POR A111MMC
TP53 0.36432 -0.26588 -0.39487 -0.66527 0.47621 -0.03163 -0.27518 0.26744
MYC -0.15383 0.38758 -0.17875 0.02019 -0.10465 0.68949 -0.05547 0.89916
SM105 SM109 A102 A104 A107 A108 A110 A111
TP53 0.54888 -0.57843 0.39086 -0.41720 -0.24722 0.43686 0.12658 0.46698
MYC 0.02869 -0.00150 0.18062 -0.15054 0.37732 -0.17062 0.22526 0.02603
SM201 SM203 A202 A204 A205 A206 A207 A208 A209
TP53 -0.12299 -0.37356 -0.06185 -0.97802 -0.51666 -0.41075 -0.16871 -0.48922 -0.44817
MYC 0.42723 0.10365 0.75227 0.08942 0.13256 0.30174 1.51943 -0.05760 -0.12850
SM201 SM203 A202 A204 A205 A206 A207 A208 A209
TP53 0.10594 -1.32617 0.28919 -0.11258 -0.94866 -0.50405 -0.70435 -0.70839 0.17935
MYC 0.16098 0.51865 1.09902 0.52595 0.23809 -0.03043 0.02984 -0.11336 -0.21899
SM201POR SM203POR A202POR A204POR A205POR A206TC A207POR A208POR
TP53 -0.41347 -0.18086 0.33278 -0.63912 0.02259 -0.16128 -0.50111 -0.23164
MYC 0.17736 -0.00824 0.43179 0.14680 0.08873 -0.05205 1.74383 -0.16978
Invasive part of LS-/TC+ UGCs
LS+ UGCs
LS-/TC+ UGCs
Mucosal LS+ part of invasive LS+ UGCs
Mucosal POR part of invasive LS-/TC+ UGCs
Mucosal TC part of invasive LS-/TC+ UGCs
LS+ part of intramucosal LS+ UGCs
Invasive POR part of LS+ UGCs
LS- part of intramucosal LS+ UGCs
Mucosal LS- part of invasive LS+ UGCs 
Figure 4 Array CGH data of MYC and TP53 in LS+ UGCs and LS−/TC+ UGCs. LS+ UGCs are divided into intramucosal cancers and invasive
cancers. Numerals mean the base 2 logarithm of the test/reference signal intensity ratios of array CGH data. Significant gains and losses are
indicated with red and green, respectively. The samples marked with and without grey margin are included in cluster B and cluster A,
respectively, in Figure 3.
Sonoda et al. BMC Medical Genomics 2013, 6:25 Page 6 of 11
http://www.biomedcentral.com/1755-8794/6/25Copy-number alterations (CNAs) common to all the
samples from the same tumour were called stemline
changes [14] and estimated to occur at the earliest stage of
tumourigenesis and to be inherent into tumour lineage.
Stemline gains of 3q26 were detected in 2/20 cases of in-
vasive LS+UGCs and none of invasive LS−/TC+UGCs.
In contrast, stemline gains of 5p15, 8p23 and 12p12 were
detected in 2/9 cases of invasive LS−/TC+UGCs but in
no case of invasive LS+UGCs. No stemline losses were
detected in any cases of UGCs.
Previous studies using chromosomal or array CGH ana-
lyses [19-27] reported that frequent CNAs in gastric
cancers (common to both UGC and DGC) were chromo-
somal gains at 3q, 5p, 7p, 8q, 13q, 17q, 20p and 20q, andlosses at 4q, 5q, 6q, 9p, 17p, 18q and 21q. In the UGCs
examined in the present study, all previously reported
CNAs were observed except gains at 17q and 20p and
losses at 5q and 6q. Gains at 8p and 12p were common in
LS−/TC+UGCs. Copy-number gains at 8q24 were com-
mon in both types of UGCs, with 4/20 cases of LS+UGCs
and 3/9 cases of invasive LS−/TC+UGCs, but these were
not stemline changes.
Impartial selection of genes reflecting the whole
genome profile
To classify UGC samples based on the overall similarity
in the profile of gene copy number changes, we used un-
supervised hierarchical cluster analysis. For this purpose,
Cluster A Cluster B 
Intramucosal LS+ UGCs Invasive LS+ UGCs Invasive LS-/TC+ UGCs 
Figure 5 Array CGH data of genes other than MYC and TP53 with significantly different T/R ratio between clusters A and B. UGCs are
divided into clusters A and B that were determined in Figure 3. The heat map indicates the base 2 logarithm of the test/reference signal intensity
ratios of array CGH data. Gains and losses are indicated with red and green, respectively.
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used in the cluster analysis from 60K to several thou-
sands. The reduced number of genes should still reflect
the whole genome profile if impartially selected. To fulfil
these conditions, we selected genes based solely on the
size of genes (the numbers of corresponding probes).
After repeated trials of cluster analyses using genes of
various minimum sizes (or probe numbers per gene), we
observed that most CNAs from the same tumour were
clustered more closely together than any samples from
another UGC case when we analysed only genes with 3
or more probes per gene: a total of 5019 genes.
Classification of UGC using hierarchical cluster analysis
We applied an unsupervised two-dimensional hierarch-
ical clustering algorithm, to a total of the 63 DNA sam-
ples from 29 UGCs. The samples were classified into
two major clusters A and B, based on similarity in the
genome profile (Figure 3). Of 63 samples, 30 LS+ UGCs
were classified into cluster A and only 7 into cluster B.
For LS−/TC+ UGCs, 8 samples were classified into clus-
ter A and 18 into cluster B. All Intramucosal LS+ UGCs
were included in cluster A. Clusters A and B had signifi-
cantly different proportions of morphological subtypes
(P = 0.0001).
Copy number alterations of MYC and TP53
Gains at 8q24 were common alterations for both LS+
and LS−/TC+ UGCs. The representative genes located atthis locus is MYC. Gains of MYC were detected in 2/11
of Intramucosal LS+ UGCs (18.2%), 6/26 of LS+ UGC
(23.1%) and 8/26 of invasive LS−/TC+ UGCs (30.1%).
The aggressive pattern (MYC+ and/or TP53−) was de-
tected in 6/11 of Intramucosal LS+UGCs (54.5%), 11/26
of invasive LS+UGCs (42.3%) and 20/26 of invasive LS−/
TC+UGCs (76.9%; Figure 4). Therefore, the aggressive
pattern was more frequently detected in invasive LS−/
TC+UGCs than in LS+ UGCs (P = 0.0195). The dor-
mant pattern (MYC− and TP53+) was not detected in
any of the UGC samples, even those from intramucosal
GCs (Figure 4).
Copy number alterations of genes other than
MYC or TP53
As mentioned above, 5p15 was one of the most frequent
gain sites in invasive LS−/TC+ UGCs (8/26; 30.7%), but
was not detected in any of the 37 intramucosal and in-
vasive LS+ UGCs (Figure 2). The target genes located at
this locus may include the telomerase reverse transcrip-
tase gene (TERT) because a TERT gain was more fre-
quently detected in invasive LS−/TC+ UGCs than
intramucosal and invasive LS+ UGCs (16/26 vs. 1/37,
P < 0.0001) (Figure 5). In contrast, losses of TERT were
detected in 4/37 samples of intramucosal and invasive
LS+ UGCs (10.8%) but not in invasive LS−/TC+ UGCs.
Welch’s t test was performed to compare the mean T/
R ratio between the samples in cluster A and those in
cluster B at each 2756 probe loci of 979 cancer-related
Table 2 List of 40 genes that have CNAs significantly different between clusters A and B
Probe name Location Name of Gene Description P-value P value after
Bonferroni correction
A_16_P41637097 Xp21.2 DMD dystrophin 4.541E-08 1.251E-04
A_14_P133591 5q21-q22 APC adenomatous polyposis coli 5.774E-08 1.591E-04
A_14_P130973 4q11-q12 *KIT v-kit Hardy-Zuckerman 4 feline sarcoma viral
oncogene homolog
1.047E-07 2.886E-04
A_14_P125447 13q12-q14 SMAD9 SMAD family member 9 1.373E-07 3.784E-04
A_14_P100439 12q24.3 *RAN member RAS oncogene family 1.876E-07 5.171E-04
A_14_P102616 20q11.2 GDF5 growth differentiation factor 5 2.828E-07 7.794E-04
A_14_P133647 11q23.3 **ETS1 v-etserythroblastosis virus E26 oncogene homolog 1 (avian) 5.603E-07 0.0015
A_14_P138640 5p14.3 CDH18 cadherin 18, type 2 6.138E-07 0.0017
A_14_P128664 18q23 ATP9B ATPase, class II, type 9B 6.474E-07 0.0018
A_14_P124801 19p12 PBX4 pre-B-cell leukemia homeobox 4 1.010E-06 0.0028
A_14_P118423 Xq28 *RAB39B member RAS oncogene family 1.573E-06 0.0043
A_14_P134602 17q11.2 NF1 neurofibromin 1 1.802E-06 0.0050
A_14_P120351 5q31.1 IL5 interleukin 5 (colony-stimulating factor, eosinophil) 1.988E-06 0.0055
A_14_P125637 6q16.1 **EPHA7 EPH receptor A7 2.153E-06 0.0059
A_14_P100300 13q12-q14 SMAD9 SMAD family member 9 2.525E-06 0.0070
A_14_P201681 7p21.1 ITGB8 integrin, beta 8 2.589E-06 0.0071
A_14_P130112 Xp22.2 *RAB9A RAB9A, member RAS oncogene family 2.949E-06 0.0081
A_14_P120484 1q41 RPS6KC1 ribosomal protein S6 kinase, 52 kDa, polypeptide 1 3.052E-06 0.0084
A_16_P16709446 4q13.1 **EPHA5 EPH receptor A5 3.584E-06 0.0099
A_14_P201127 2q32 DLX2 distal-less homeobox 2 3.703E-06 0.0102
A_14_P126957 11p11.2 **SPI1 spleen focus forming virus (SFFV) proviral
integration oncogene
4.334E-06 0.0119
A_14_P104667 8q22.2 STK3 serine/threonine kinase 3 4.386E-06 0.0121
A_14_P137889 14q13.3 NKX2-8 NK2 homeobox 8 5.393E-06 0.0149
A_14_P109970 1p36.1-p35 **EPHB2 Eph receptor B2 6.637E-06 0.0183
A_14_P118116 Xp21.2 DMD dystrophin 8.087E-06 0.0223
A_16_P01378894 5q34 ATP10B ATPase, class V, type 10B 8.165E-06 0.0225
A_14_P139456 17q25.1 *RAB37 member RAS oncogene family 1.001E-05 0.0276
A_14_P111361 17q21.2 KRT33B keratin 33B 1.069E-05 0.0295
A_14_P134909 19p13.3-p13.2 INSR insulin receptor 1.110E-05 0.0306
A_16_P02740008 13q12 ATP8A2 ATPase, aminophospholipid transporter, class I,
type 8A, member 2
1.129E-05 0.0311
A_14_P102858 1q42 KIAA1804 mixed lineage kinase 4 1.155E-05 0.0318
A_14_P113857 12p13 **ETV6 ets variant 6 1.172E-05 0.0323
A_14_P115054 16q22.3 ZFHX3 zinc finger homeobox 3 1.180E-05 0.0325
A_14_P138431 1p32-p31 ROR1 receptor tyrosine kinase-like orphan receptor 1 1.209 E-05 0.0333
A_18_P22746653 3p25.3 ATP2B2 ATPase, Ca++ transporting, plasma membrane 2 1.282E-05 0.0353
A_14_P105811 11q13 MEN1 multiple endocrine neoplasia I 1.318E-05 0.0363
A_14_P136621 18q11.2 CDH2 cadherin 2, type 1, N-cadherin (neuronal) 1.420E-05 0.0391
A_14_P103176 1p34.3 **EPHA10 EPH receptor A10 1.455E-05 0.0401
A_16_P17370843 5q34 ATP10B ATPase, class V, type 10B 1.556E-05 0.0429
A_14_P108129 5p15.33 *TERT telomerase reverse transcriptase 1.584E-05 0.0436
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Table 2 List of 40 genes that have CNAs significantly different between clusters A and B (Continued)
A_16_P19750359 13q12 ATP8A2 ATPase, aminophospholipid transporter, class I,
type 8A, member 2
1.586E-05 0.0437
A_14_P200005 1p36 ATP13A2 ATPase type 13A2 1.586E-05 0.0437
A_16_P01183532 5p15.2 **TRIO trio Rho guanine nucleotide exchange factor 1.786E-05 0.0492
In the column of gene name, “*” indicates genes related to tumour growth and “**” those related to invasion and metastasis.
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had significantly different mean T/R ratios between Clus-
ters A and B at a level of P < 0.05 after Bonferroni cor-
rection (Table 2). Of the 40 genes, 6 genes (KIT, RAN,
RAB39B, RAB9A, RAB37 and TERT), including proto-
oncogenes, have been implicated in enhanced tumour
growth, and 8 genes (ETS1, SPI1, ETV6, EPHA7, EPHA5,
EPHB2, EPHA10 and TRIO) in invasion/metastasis and 3
genes (APC, NF1 and MEN1) in tumour suppression
(Table 2). Most of log2 T/R ratios of the 43 distinguishing
gene probes were of opposite sign between clusters A and
B, with greater in absolute values in cluster B (Figure 5).
Discussion
Based on chromosomal CGH analysis, we have reported
that there are two distinct UGC lineages: the LS+ lineage
derived from early SIG and LS−/TC+ lineage dedif-
ferentiated from TUB [15]. The former is characterized
by LS and the latter by a small TC. However, there are
also UGCs without these morphological lineage markers.
In the present study, we classified UGC based on simi-
larity in the whole genome copy number profile among
samples using unsupervised hierarchical cluster analysis
and examined the correlation between this gene-based
classification and morphological lineage markers.
Using 5019 large genes and aCGH data from 63 DNA
samples from 29 UGCs, we confirmed that most of the
samples examined from the same tumour were clustered
more closely together than in any other sample, thus ful-
filling the criteria for our internal standard. On the basis
of this observation, we performed an unsupervised two-
dimensional hierarchical cluster analysis. All the samples
were classified into two major clusters A and B (Figure 3).
Cluster A was rich in LS+UGCs, whereas cluster B was
rich in LS−/TC+UGCs. This difference was statistically
significant (P = 0.0001) and indicates that the classification
by the presence or absence of LS and TC is well correlated
with the genomic-profile-based classification and validates
the LS+ and LS−/TC+ as lineage markers.
All the intramucosal LS+UGCs were included in cluster
A, suggesting that most of UGCs in cluster A were
derived from intramucosal SIG, and that the LS−/TC+
UGCs in cluster A may have secondarily lost LS. The
LS−/TC+UGCs in cluster A may also be derived from
SIG, as suggested by chromosomal CGH studies [15]. In
contrast, LS in advanced LS+UGCs in cluster B (A107,A108 and A110) was virtually indistinguishable morpho-
logically but showed genomic constitutions different from
LS in cluster A. This may be a kind of phenocopy; a frac-
tion of LS+UGCs were considerably similar in genomic
profile to LS−/TC+UGCs. Although LS exhibits regular
cell proliferation and differentiation and a superficially
spreading dormant growth [13], it is suggested that LS it-
self is not a marker of persistent tumour dormancy but
has the potential to progress to an advanced stage with
the prognosis as poor as that for LS−/TC+UGCs. This
situation may resemble that in chronic myeloid leukaemia,
in which blastic transformation occurs after a dormant
phase of well retained cellular differentiation.
Most UGCs exhibited the aggressive genomic pattern
(TP53− and/or MYC+), even 55% of intramucosal LS+
UGCs, an incidence comparable to that in invasive UGCs.
The dormant pattern (MYC− and TP53+) was not de-
tected in any of the UGC samples, even in intramucosal
UGCs. These intramucosal UGCs are distinct from early
DGCs, in which 70% are of the dormant type [16]. There-
fore, TP53 and MYC are not as useful prognostic markers
for UGCs.
To explore other genes important for differentiation
of genetic lineage and for UGC prognosis, we first com-
pared the profiles of chromosomal copy-number alter-
ations (CNAs) between LS+ and LS−/TC+ UGCs. As
shown in Figure 2, CNAs detected in LS+ tumours but
not in LS−/TC+ tumours, include 3q26 gain, a locus
likely to include SKIL because the average SKIL copy
number was greater in LS+ tumours than in LS−/TC+
tumours (P = 0.0060). SKIL encodes SnoN protein that
is proto-oncogenic by antagonizing cytostatic responses
of TGF-β [28,29] and anti-oncogenic by activating p53
[30]. Those CNAs with the opposite pattern (present in
LS−/TC+ tumours but not in LS+ tumours) were gains
at 5p15, 8p23 and 12p12. The target genes at 5p15 and
12q12 include TERT, and KRAS, respectively because
gains of TERT, and KRAS were more frequently
detected in invasive LS−/TC+ UGCs than intramucosal
and invasive LS+ UGCs (P < 0.0001 and P = 0.0032, re-
spectively). No target gene was detected at 8q23.
Our second approach to identify lineage-specific CNAs
was a screening of genes (from 979 cancer-related genes)
that indicated significantly different mean T/R ratios be-
tween the samples of clusters A and B. We selected 40
genes that were significantly different between clusters
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related to enhanced tumour growth and 8 to invasion/me-
tastasis (Table 2). As shown in Figure 5, genes that drive
tumourigenesis were more common in cluster B and
showed larger amplitude CNAs. Thus, UGCs in cluster B
may be more dependent on oncogenic genomic alterations
and less on environmental and epigenetic alterations than
those in cluster A.
The possible drivers of tumour growth screened in-
cluded KIT, TERT, and RAS family genes. KIT encodes a
receptor tyrosine kinase that is activated by stem cell
factor binding and initiates numerous signal transduc-
tion pathways linked with the process of apoptosis,
proliferation and tumorigenesis [31]. RAS family genes
encode small GTPase that plays a key role in transduction of
signals from receptor kinase to the pathways of various cellu-
lar processes [32]. TERT encodes the telomerase catalytic
subunit that plays not only an important role in cellular
immortalization by telomere elongation [33,34] but also acti-
vates cell proliferation [35]. The possible drivers of invasion
and metastasis screened include ETS1 and Ephrin receptor
genes. ETS1 encodes a transcription factor, Ets1 proto-
oncoprotein that promotes invasiveness and is an indicator
of poor outcome in epithelial cancers through regulation of
MMP1, MMP3, MMP9, uPA, VEGF and VEGF receptor ex-
pression [36]. Ephrin receptor genes, EPH39B, A7, A5 and
A10 genes encode the ephrin receptor with tyrosine kinase
activity that affects tumor growth, invasiveness, angiogenesis,
and metastasis [37].
There were no significant differences in the mean copy
number of CDH1 and its transcriptional repressor genes
(SNAI1, SNAI2, ZEB1, ZEB2, TWIST1, etc.) between the
clusters A and B, although these genes were reportedly
associated with a poorly differentiated phenotype and
poor clinical outcome [38]. However, these genes may
still participate in UGC tumourigenesis through epigen-
etic silencing [39].
We are now extending this study to to validate UGC-
associated genes as indicated by aCGH by quantitative
PCR and to correlate their genomic copy number to
gene expression and prognosis. Thereafter, using quanti-
tative PCR analyses instead of aCGH, similar analyses
should be applied to a greater number of tumour cases
with known outcomes.
Conclusions
Unsupervised cluster analyses of aCGH data of multiple
samples from early and advanced UGCs have demon-
strated that early UGCs, including LS+ types in which po-
larity of cell proliferation and differentiation is well
retained, have aggressive potential. Therefore, eradication
of UGCs at early stages may thus contribute to better pa-
tient survival. In addition, it was observed that the two
UGC lineages, one derived from early SIG and the otherfrom TUB, have different genomic copy-number alteration
profiles, resulting in different sets of genes contributing to
tumourigenesis. The latter lineage from TUB may be more
dependent on genomic copy-number alterations and have
a poorer outcome than UGCs derived from SIG.
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